Immuron Limited — FY2022 Form 20-F
Period: Fiscal year ended June 30, 2022. The request metadata says “2021 Q4,” but the filing is an annual report for FY2022, not a quarterly filing. Financial amounts below are Australian dollars (A$), unless otherwise stated. Statements are prepared under IFRS.
Business context
Immuron is an Australian commercial- and clinical-stage biopharmaceutical company developing oral polyclonal antibodies from hyper-immune bovine colostrum. Its marketed products are Travelan, sold in Australia, Canada and the U.S. (as a dietary supplement in the U.S.), and Protectyn, sold in Australia. Prescription drug candidates include IMM-124E/Travelan for enteric infections and travelers’ diarrhea, IMM-529 for recurrent C. difficile infection, and a Campylobacter/ETEC therapeutic developed with U.S. Naval Medical Research Center collaborators.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue from customers | A$765,193 | A$145,776 |
| Gross profit / gross margin | A$523,502 / 68% | A$94,705 / 65% |
| Other income | A$957,725 | A$617,110 |
| Operating loss | A$(2,869,855) | A$(8,379,908) |
| Net loss | A$(2,854,254) | A$(8,384,465) |
| Operating cash used | A$(3,147,793) | A$(4,078,747) |
| Cash and cash equivalents at year-end | A$22,110,278 | A$25,047,281 |
| Total assets / total liabilities | A$24,855,824 / A$1,678,423 | A$27,053,106 / A$1,158,049 |
Revenue increased 425%, reflecting recovery in Travelan and Protectyn sales as travel restrictions eased. FY2022 included A$306,595 of Henry M. Jackson Foundation grant income, A$369,045 of MTEC grant income, and an A$257,500 Australian R&D tax incentive. There was no COVID-19 government assistance income in FY2022, versus A$161,600 in FY2021.
Operating expenses fell to A$4,598,640 from A$7,749,430. General and administrative expense declined by A$2.57 million, primarily because share-based payment expense fell to about A$94,891 from A$2.12 million; research and development expense fell to A$657,715 from A$1,367,054, which the company attributed partly to pandemic disruption. Selling and marketing expense increased to A$416,537 from A$287,684.
Cash declined A$2.94 million during FY2022. The company reported no credit facilities and low total liabilities; year-end liabilities primarily included payables, provisions and lease liabilities, rather than material borrowings. Management said available cash was expected to fund operations and R&D for at least 12 months from the financial statements’ issuance date, and prepared the statements on a going-concern basis. No dividends were declared or recommended. The company reported A$68.43 million in accumulated losses.
Material changes and unusual items
- Travelan and Protectyn sales recovered sharply from the pandemic-affected prior year, but remained below FY2020 revenue of A$2.52 million. FY2022 revenue was concentrated in Travelan U.S. sales of A$501,228; reported U.S. sales were a significant part of the rebound.
- The FY2021 loss included A$759,765 of inventory impairment and A$582,528 of foreign-exchange losses. FY2022 reported no net impairment loss and A$247,558 of foreign-exchange gains, in addition to lower expenses; these factors contributed to the smaller net loss.
- Cash was lower than FY2021, when a public offering generated substantial financing proceeds. FY2022 had net financing cash outflow of approximately A$42,448 and no new equity-raising proceeds shown in the cash flow statement.
- Ordinary shares outstanding were 227,798,346 at June 30, 2022, versus 227,246,596 a year earlier. The company’s NASDAQ-listed warrants expired in June 2022.
Outlook, development and risks
- Management’s stated strategy is to grow Travelan and Protectyn sales while advancing clinical programs and collaborations. It provided no quantified financial guidance or revenue forecast.
- Management described cash as sufficient for at least 12 months from issuance of the statements, but said longer-term development and commercialization may require additional funding. Future financing could dilute shareholders; a funding shortfall could force delays, reductions or discontinuation of programs.
- The DoD-funded Travelan dose-optimization study was planned to test a once-daily 1,200 mg regimen in up to 60 volunteers, with results intended to inform later pivotal studies. The company planned to file an IND by the end of 2022 and start the study in 2023; these were plans, not completed milestones in the filing.
- The Campylobacter/ETEC IND filed by NMRC was placed on FDA clinical hold in 2022 because the FDA requested additional information on dosing, safety monitoring and risk mitigation. NMRC was preparing a response; trial timing depended on FDA review and resolution of the hold.
- IMM-529’s planned U.S. Phase I/II study for recurrent C. difficile was still in protocol and site-planning stages. The prior Israel study was closed after only 9 of 60 planned patients enrolled. The company said obtaining orphan-drug designation could be challenging.
- IMM-124E studies for NASH, severe alcoholic hepatitis and pediatric NAFLD did not demonstrate the intended clinical benefit, and the company said it would not continue development for those indications. Separately, SARS-CoV-2 research was deprioritized in August 2022 because its mechanism remained unclear and the changing treatment landscape complicated clinical development.
- Principal risks include continuing operating losses, uncertain clinical and regulatory outcomes, reliance on third-party clinical organizations and manufacturers, dependence on a sole lead-compound manufacturer, limited commercial-scale manufacturing capability, market acceptance and competition, and possible need for further capital. Travelan sales had been significantly affected by COVID-19 travel restrictions.
- The filing reports no material legal proceedings or contingent liabilities at June 30, 2022. The auditor issued an unqualified opinion on the IFRS financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an ICFR attestation.
Important facts for investors to verify
- Confirm current cash, operating burn and financing runway against subsequent filings, especially given the stated 12-month runway and planned clinical spending.
- Check FDA and NMRC updates on the Campylobacter/ETEC clinical hold, and verify whether the planned Travelan IND, dose-optimization study and later pivotal program proceeded.
- Verify IMM-529 trial initiation, enrollment plans, regulatory status and the feasibility of the proposed recurrent-CDI indication.
- Assess whether the sales rebound persisted beyond FY2022 and how much sales depend on travel recovery, U.S. channels, discounts and a small number of major customers.
- Review inventory valuation and impairment disclosures: the audit report describes A$430,932 of raw-material impairment provision in the FY2022 inventory balance, while other filing passages state that no raw-material impairment was recognized during FY2022. The filing text does not clearly reconcile these statements.
- Review grant and R&D tax incentive eligibility and collection. The A$257,500 FY2022 incentive was estimated, and the auditor identified it as a critical audit matter; a separate additional MTEC funding proposal was described as eligible but not immediately funded.